Sensitivity and specificity of HPV testing: What are the facts?

Cytopathology

Volumn 24, Issue 5, 2013, Pages 283-288

  Dudding, N ^a   Crossley, J ^b  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; HUMAN; HUMAN PAPILLOMAVIRUS TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; WART VIRUS;

FEMALE; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84884693034     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12104     Document Type: Article

References (25)

1. Cubie H, Cuschieri K. Understanding HPV tests and their appropriate applications. Cytopathology 2013;24:289-308.
2. Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-82.
3. Farnsworth A. Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol 2011;55:307-12.
4. Zhao C, Amin M, Weng B et al. Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3. Arch Pathol Lab Med 2013;137:942-7.
5. Arbyn M, Sasieni P, Clavel C et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl. 3):S3/78-89.
6. Denton KJ, Herbert A, Turnbull LS et al. The revised BSCC terminology for abnormal cervical cytology. Cytopathology 2008;19:137-57.
7. NHS Cervical Screening Programme. HPV-triage flowchart. Available at: http://www.cancerscreening.nhs.uk/cervical/hpv-triage-test-flowchart.pdf (Accessed 19 August 2013).
8. Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011;105:983-8.
9. Cotton S, Sharp L, Little J et al. The role of human papillomavirus testing in the management of women with borderline and other low-grade abnormalities: multicentre randomised controlled trial. BJOG 2010;117:645-59.
10. Moss S, Kelly R, Legood R et al. Evaluation of sentinel sites for HPV triage and test of cure. Report to the NHS Cancer Screening Programmes. September 2011. Available at: http://www.cancerscreening.nhs.uk/cervical/sentinelfinalreport.pdf (Accessed 25 August 2013).
11. Blanks RG. ABC3 Part II: a review of the new criterial for evaluating cervical cytology in England. Cytopathology 2013;24:166-76.
12. Kitchener HC, Walker PG, Nelson L et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001-7.
13. Bowring J, Albrow R, Fisher A et al. A prospective study of human papillomavirus (HPV) testing to resolve uncertaintly in colposcopy. Cytopathology 2013;24:309-13.
14. Szarewski A, Mesher D, Cadman L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73.
15. Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011;47:864-71.
16. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97. Erratum in: N Engl J Med 2008;359: 1637.
17. Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
18. Stoler MH, Wright TC, Sharma A et al. High-risk human papillomavirus testing in women with ASC-US cytology. Am J Clin Pathol 2011;135:468-75.
19. Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
20. Stoler MH, Castle PE, Solomon D et al.; American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007;127:335-7.
21. Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med 2005;43:1171-7.
22. Office for National Statistics. Statistics bulletin. Cancer registrations in England, 2010. Available at: www.ons.gov.uk/dcp171778_263537.pdf (Accessed 25 August 2013).
23. Woodman CB, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
24. Sundström K, Ploner A, Dahlström LA et al. Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer. Cancer Epidemiol Biomarkers Prev 2013;22:150-8.
25. Preisler S, Rebolj M, Untermann A et al. Prevalence of human papillomavirus in 5, 072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS ONE 2013;8:e59765.